What to look forward to in GaBI Journal, 2022, Issue 2
Substitution and interchangeability: time for a conversation?
On statistical evaluation for interchangeability of biosimilar products
A case study of AstraZeneca’s omeprazole/esomeprazole chiral switch strategy
Manufacture and regulation of cell, tissue and gene therapy products: global perspectives, challenges and next steps
Front-loading biosimilar development with analytical characterization